After attending the Marcus Evans Group’s 7th Annual OI Summit, I was delighted to see the evolution currently happening in the OI stratosphere. I was privy to a few surprises in the lineup from non-traditional players in the OI space, making this dynamic open innovations platform technologically enticing.
CareFusion Corp. said Thursday it will pay about $41 million to resolve a government investigation into marketing practices for its antiseptic ChloraPrep. The investigation also covered CareFusion's relationships with health care professionals. The company said it agreed to the settlement in principle and is also entering into a non-prosecution agreement.
The jury in federal court in Louisville awarded $6.25 million in punitive damages and $994,000 in compensatory damages on Wednesday to the family of Breanna Sadler of Vine Grove. Sadler's family sued Advanced Bionics in 2011 — about three years after the girls' cochlear implant made her ill.
The bionic legs he uses cost $60,000 a piece, are hydraulically operated and equipped with microchips and a gyroscope that sense when to relax and stiffen to help him walk. Walter Reed was involved in developing the legs, said Zach Harvey, former prosthetics chief at Walter Reed.
Hundreds of women who received faulty breast implants gathered Wednesday in a makeshift courthouse in the south of France for the fraud trial of five executives accused of using cheap industrial silicone to fill tens of thousands of implants that were sold around the world.
The Supreme Court grapples Monday with the question of whether human genes can be patented, and the ultimate answer could reshape U.S. medical research, the fight against diseases like breast and ovarian cancer and the multi-billion dollar medical and biotechnology business.
Abbott Laboratories is recalling its FreeStyle InsuLinx Blood Glucose Meters after finding that they display and store incorrect test results for dangerously high blood sugar levels. The company says the meters will display and store readings for blood glucose levels of 1,024 milligrams per deciliter or higher at much lower levels.
The company said it is taking some production lots of its DuraGen and Dural Graft Matrix products off the market because of possible "deviations from approved manufacturing processes." The products were made at a facility in Añasco, Puerto Rico, between December 2010 and May 2011 and between November 2012 and March 2013.
The high-tech helper is under scrutiny over reports of problems, including several deaths that may be linked with it and the high cost of using the robotic system. There also have been a few disturbing, freak incidents: a robotic hand that wouldn't let go of tissue grasped during surgery and a robotic arm hitting a patient in the face.
A federal appeals court says that a Johnson & Johnson heart stent does not infringe a patent held by a doctor and inventor, overturning a $482 million decision against the company. The three-judge panel said a lower court misinterpreted the company's patent and should not have ruled in favor of Bruce Saffran, a doctor from Princeton, N.J.
Sony Corp. and Olympus Corp. said Wednesday they will merge their medical businesses on April 16, after it was postponed twice due to a delay in obtaining regulatory approval overseas. The two companies initially planned to set up the new medical equipment company, to be named Sony Olympus Medical Solutions Inc., by the end of last year.
A researcher at the Medical College of Wisconsin is charged with espionage after prosecutors say he stole details of a cancer-fighting compound that he wanted to share with China. Prosecutors say Hua Jun Zhao stole the compound, C-25, and data that led to its development.
India's Supreme Court on Monday rejected drug maker Novartis AG's attempt to patent an updated version of a cancer drug in a landmark decision that health activists say ensures poor patients around the world will get continued access to cheap versions of lifesaving medicines.
The Department of Health and Human Services' inspector general said the increasingly common practice is "inherently suspect" and may violate anti-kickback laws, according to the special fraud alert. The agency has only issued a handful of these national fraud alerts in the past 20 years and the warning sends a strong message to doctors.
Brown University has signed a deal with Lifespan to market biomedical discoveries and inventions by researchers in the state's largest health system. The university said Monday that its Technology Ventures Office will help manage and provide marketing, licensing, business development and other services for certain new discoveries made by Lifespan scientists.
Johnson & Johnson has announced a voluntary recall for all its OneTouch VerioIQ blood glucose meters in the U.S. because they do not provide a warning when a diabetic's blood sugar level is dangerously high. Instead, the meters turn off. The meters are made by J&J's LifeScan unit, which will issue a free replacement meter to all patients.
Heart care is in the midst of a transformation. Many problems that once required sawing through the breastbone and opening up the chest for open heart surgery now can be treated with a nip, twist or patch through a tube. These minimal procedures used to be done just to unclog arteries and correct less common heart rhythm problems.
The Supreme Court will soon decide whether generic drug manufacturers can be sued in state court for a drug's design defects after federal officials approved the brand-name version. The justices Tuesday heard arguments from generic manufacturer Mutual Pharmaceutical Co, Inc.
Cynosure is buying Palomar Medical Technologies Inc. in a cash-and-stock deal valued at about $294 million. Both Cynosure and Palomar's products include cosmetic laser and intense pulsed light systems. Both companies' boards unanimously approved the deal, which is expected to close in the third quarter.
Genetic analysis instrument maker Illumina Inc. said Friday that a federal jury ruled against it in a patent infringement trial, and ordered the San Diego company to pay $96 million in damages to Syntrix Biosystems. The jury found that Illumina's BeadChip products infringed on a patent belonging to Syntrix.
Orthopedic maker Stryker Corp. said Tuesday that it received a warning from government regulators about quality control issues and unapproved marketing of medical devices. The company said it got the letter from the Food and Drug Administration following a November inspection of its Portage, Mich., facility.
By injecting the aforementioned inebriated mice with nanocapsules full of enzymes that are instrumental in alcohol metabolism, researchers have not only sobered the little vermin, but created a unique drug delivery technology that could disrupt the medical industry.
Early results from a key study of Boston Scientific Corp.'s Watchman device suggested it is safer than previous testing found, but may not be better than a drug that is used now for preventing strokes, heart-related deaths and blood clots in people with atrial fibrillation over the long term.
Jurors on Friday awarded the damages in 65-year-old Loren Kransky's negligence and defective design suit against the giant health care company and its DePuy Orthopaedics subsidiary. It's the first of thousands of similar cases that attorneys say left people with crippling problems or in need of other replacement surgeries.
It's the first verdict in about 4,000 lawsuits filed against the giant health products maker based in New Brunswick, N.J. At least one plaintiff has won a lawsuit against one of the other 30-plus makers of the once-popular implants, used to lift sagging pelvic organs back into place.